8-K: ACELYRIN Completes Merger with Alumis, Becoming a Wholly Owned Subsidiary

ACELYRIN, Inc. has completed its merger with Alumis Inc. on May 21, 2025, resulting in ACELYRIN becoming a wholly-owned subsidiary of Alumis.

Summary

• ACELYRIN, Inc. completed its merger with Alumis Inc. on May 21, 2025.
• As a result of the merger, ACELYRIN is now a wholly-owned subsidiary of Alumis.
• Each share of ACELYRIN common stock was converted into the right to receive 0.4814 shares of Alumis common stock, plus cash in lieu of fractional shares.
• Outstanding options to purchase ACELYRIN common stock with an exercise price of $18.00 or less were converted into options exercisable for Alumis common stock.
• Options with an exercise price greater than $18.00 were cancelled without consideration.
• Restricted stock units (RSUs) and performance stock units (PSUs) were also converted into Alumis equity awards.
• ACELYRIN's stock has been delisted from the Nasdaq Global Select Market.
• The company intends to terminate the registration of ACELYRIN common stock under the Securities Exchange Act of 1934.
• Alan Colowick, Patrick Machado, Beth Seidenberg, Bruce C. Cozadd, Dan Becker, Dawn Svoronos, Lynn Tetrault, Mina Kim and Henry O. Gosebruch ceased serving as members of the board of directors of ACELYRIN.
• The executive officers of ACELYRIN also ceased to be executive officers of ACELYRIN.
• The certificate of incorporation and bylaws of ACELYRIN were amended and restated to match those of Arrow Merger Sub, Inc.

Sentiment

Score: 7

Explanation: The document is factual and reports the completion of a previously announced merger. The sentiment is neutral, reflecting the completion of a corporate action.

Positives

• The merger has been successfully completed.

Negatives

• ACELYRIN's common stock has been delisted from the Nasdaq.
• All directors and executive officers of ACELYRIN have departed following the completion of the merger.
• Options with an exercise price greater than $18.00 were cancelled without consideration.

Risks

• The delisting from Nasdaq may reduce liquidity for former ACELYRIN stockholders.
• The integration of ACELYRIN into Alumis may present operational challenges.

Future Outlook

The document does not provide specific forward-looking statements beyond the completion of the merger and subsequent delisting and deregistration activities.

Industry Context

The merger reflects a trend of consolidation within the biotechnology industry, potentially driven by the need to diversify pipelines, share resources, and achieve economies of scale.

Comparison to Industry Standards

• The exchange ratio of 0.4814 shares of Alumis for each share of ACELYRIN can be compared to other recent biotech mergers to assess its relative value.
• Comparable transactions, such as the acquisition of [hypothetical company A] by [hypothetical company B] at a [hypothetical exchange ratio], can provide a benchmark.
• The cancellation of out-of-the-money options (exercise price greater than $18.00) is a standard practice in mergers.

Management Changes

Corporate Governance

Stakeholder Impact

• ACELYRIN's shareholders now hold shares in Alumis.
• ACELYRIN's employees are now employees of a wholly-owned subsidiary of Alumis.
• ACELYRIN's suppliers and customers will now interact with Alumis through ACELYRIN.

Next Steps

• File Form 25 with the SEC to delist ACELYRIN Common Stock from Nasdaq.
• File a Certification and Notice of Termination of Registration on Form 15 with the SEC to terminate registration of ACELYRIN Common Stock.

Key Dates

Keywords

merger, ACELYRIN, Alumis, acquisition, delisting, subsidiary, common stock, equity awards